Field Safety Notices: 23-27 March 2026
UKField Safety Notices: 23-27 March 2026
Recalling Firm: MHRA
Reason for Recall / Hazard
List of field Safety Notices for 23-27 March 2026...
Product Description & Identification
List of field Safety Notices for 23-27 March 2026
Affected Products
Field Safety Notices: 23-27 March 2026
Additional Source Details
| Field | Value |
|---|---|
| Guid | tag:www.gov.uk,2005:/drug-device-alerts/field-safety-notices-23-27-march-2026 |
| Link | https://www.gov.uk/drug-device-alerts/field-safety-notices-23-27-march-2026 |
| Pub Date | 2026-03-31T09:07:32+01:00 |
| Extracted category | devices |
Check Other Products In Your Household
Free ToolsSafety recalls are issued daily across foods, medications, vehicles, and electronics. Use our instant tools to check your home for active safety warnings:
Overview
- Recalling FirmMHRA
- Risk LevelMedical Device Alert
- DistributionUnited Kingdom
📢 Share Warning
Alert family and friends to keep them safe. Copy this quick alert message:
🚨 SAFETY ALERT: MHRA - Field Safety Notices: 23-27 March 2026 Check if your household is affected: https://therecallfile.com/recalls/field-safety-notices-23-27-march-2026/UK-MHRA-field-safety-notices-23-27-march-2026
Join Alertlist
Get instant email updates whenever critical safety recalls like this are published.
Related Recalls
UKField Safety Notices: 13 to 17 July 2026
Field Safety Notices: 13 to 17 July 2026
List of Field Safety Notices from 13 to 17 July 2026....
FDA DevicesAquacel Ag Surgical SP REF: 413556 9cm x 15cm/3.5 in. x 6 in., Sterile R
Aquacel Ag Surgical SP REF: 413556 9cm x 15cm/3.5 in. x 6 in., Sterile R
Surgical dressing manufactured out of specification (greater thickness).
FDA DevicesGSP Neonatal GALT Kit. Product Codes: 3303-001U, 3303-0010. in vitro diagnostic. Used in FLUORESCENT PROC. (QUAL), GALACTOSE-1-PHOSPHATE URIDYL TRANSFERASE.
GSP Neonatal GALT Kit. Product Codes: 3303-001U, 3303-0010. in vitro diagnostic. Used in FLUORESCENT PROC. (QUAL), GALACTOSE-1-PHOSPHATE URIDYL TRANSFERASE.
Reduction in the on-board stability of the GSP GALT assay. This may increase the likelihood of run-QC failures and consequently delay the reporting of patient results.